We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$316M
AUM Growth
-$26.1M
Cap. Flow
+$40.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
62.9%
Holding
48
New
11
Increased
11
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.2M
2
PCRX icon
Pacira BioSciences
PCRX
+$12M
3
INSP icon
Inspire Medical Systems
INSP
+$10.1M
4
MDT icon
Medtronic
MDT
+$7.53M
5
DXCM icon
DexCom
DXCM
+$7.04M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$8.8M
3
CNC icon
Centene
CNC
+$7.7M
4
UNH icon
UnitedHealth
UNH
+$7.21M
5
MRVI icon
Maravai LifeSciences
MRVI
+$3.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.39%
2 Industrials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
26
iRhythm Holdings
IRTC
$3.96B
$3.3M 1.05%
35,000
-1,030
-3% -$105K
PEN icon
27
Penumbra
PEN
$12.7B
$3.27M 1.04%
+13,500
New +$3.75M
STTK icon
28
Shattuck Labs
STTK
$707M
$3.23M 1.02%
2,123,000
+13,380
+0.6% +$30.5K
DSGN icon
29
Design Therapeutics
DSGN
$946M
$2.84M 0.9%
+1,203,745
New +$5.61M
BBSI icon
30
Barrett Business Services
BBSI
$833M
$1.93M 0.61%
+85,548
New +$1.97M
CMPX icon
31
Compass Therapeutics
CMPX
$432M
$1.84M 0.58%
935,157
-148,840
-14% -$368K
ALKS icon
32
Alkermes
ALKS
$7.95B
$1.82M 0.58%
65,000
-82,554
-56% -$2.42M
LBPH
33
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.79M 0.57%
321,154
-413,743
-56% -$2.66M
NUVB icon
34
Nuvation Bio
NUVB
$2.34B
$1.41M 0.45%
1,050,000
-50,000
-5% -$83.2K
AGL icon
35
Agilon Health
AGL
$1.55B
$1.4M 0.45%
3,163
-837
-21% -$378K
BMEA icon
36
Biomea Fusion
BMEA
$125M
$1.3M 0.41%
+94,817
New +$1.71M
CHE icon
37
Chemed
CHE
$6.84B
$1.3M 0.41%
+2,500
New +$1.3M
EOLS icon
38
Evolus
EOLS
$587M
$1.16M 0.37%
+126,982
New +$1.14M
ZYME icon
39
Zymeworks
ZYME
$2.02B
$675K 0.21%
+106,405
New +$786K
ERAS icon
40
Erasca
ERAS
$6.31B
$521K 0.17%
264,710
-1,292,660
-83% -$3.31M
ELUT icon
41
Elutia
ELUT
$39M
$36.6K 0.01%
25,594
-298,831
-92% -$523K
ALDX icon
42
CALL
Aldeyra Therapeutics
ALDX
$89.9M
– –
-671,200
Closed -$10K
ALDX icon
43
Aldeyra Therapeutics
ALDX
$89.9M
– –
-149,511
Closed -$1.25M
MODV
44
DELISTED
ModivCare
MODV
– –
-16,023
Closed -$724K
MRVI icon
45
Maravai LifeSciences
MRVI
$1.14B
– –
-314,300
Closed -$3.91M
TNET icon
46
PUT
TriNet
TNET
$3.23B
– –
-1,604,993
Closed -$40.1K
STLN
47
Starling Oncology
STLN
$629M
– –
-455,302
Closed -$251K
UNH icon
48
UnitedHealth
UNH
$353B
– –
-15,000
Closed -$7.21M
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2023 Portfolio in Review

As of Q3 2023, Prosight Management held 48 positions worth $316M, down 7.6% from $342M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $40.1M of net new capital in Q3 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Inspire Medical Systems: 40,000 shares worth $7.94M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $9.48M trimmed.

  • Prosight Management's largest Q3 2023 buy was Inspire Medical Systems: 40,000 shares worth $7.94M.
  • Prosight Management added most to Lakefront Biotherapeutics American Depositary Shares in Q3 2023, an estimated $12.2M increase.
  • Prosight Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $9.48M.
  • Prosight Management fully exited UnitedHealth in Q3 2023, selling an estimated $7.21M.
  • Prosight Management's ten largest holdings make up 63% of its $316M portfolio in Q3 2023.
  • Prosight Management opened 11 new positions and closed 7 in Q3 2023.
  • Prosight Management's portfolio value fell 7.6% quarter-over-quarter to $316M.

Based on Prosight Management's 13F filing for Q3 2023, filed 14 Nov 2023.